CN115052867A - 一种吩噻嗪类铁死亡抑制剂及其制备方法和用途 - Google Patents

一种吩噻嗪类铁死亡抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN115052867A
CN115052867A CN202080080607.9A CN202080080607A CN115052867A CN 115052867 A CN115052867 A CN 115052867A CN 202080080607 A CN202080080607 A CN 202080080607A CN 115052867 A CN115052867 A CN 115052867A
Authority
CN
China
Prior art keywords
alkyl
heterocyclic group
substituted
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080080607.9A
Other languages
English (en)
Other versions
CN115052867B (zh
Inventor
杨胜勇
李琳丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Henghao Innovation Technology Co ltd
Original Assignee
Chengdu Henghao Innovation Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Henghao Innovation Technology Co ltd filed Critical Chengdu Henghao Innovation Technology Co ltd
Publication of CN115052867A publication Critical patent/CN115052867A/zh
Application granted granted Critical
Publication of CN115052867B publication Critical patent/CN115052867B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种吩噻嗪类铁死亡抑制剂及其制备方法和用途。具体提供了式I所示的化合物、或其盐、或其立体异构体。本发明合成的吩噻嗪类化合物对铁死亡有良好的抑制作用并且具有良好的用药安全性，可用于制备铁死亡抑制剂，也可以用于制备治疗神经退行性疾病、肿瘤、组织缺血再灌注损伤、脑卒中、心血管疾病、肾衰竭以及糖尿病并发症等与铁死亡相关的疾病的药物。
Figure DDA0003655425620000011

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN202080080607.9A 2019-11-21 2020-11-18 一种吩噻嗪类铁死亡抑制剂及其制备方法和用途 Active CN115052867B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911150501 2019-11-21
CN2019111505017 2019-11-21
PCT/CN2020/129707 WO2021098715A1 (zh) 2019-11-21 2020-11-18 一种吩噻嗪类铁死亡抑制剂及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN115052867A true CN115052867A (zh) 2022-09-13
CN115052867B CN115052867B (zh) 2024-08-23

Family

ID=75979945

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080607.9A Active CN115052867B (zh) 2019-11-21 2020-11-18 一种吩噻嗪类铁死亡抑制剂及其制备方法和用途

Country Status (3)

Country Link
US (1) US20230021442A1 (zh)
CN (1) CN115052867B (zh)
WO (1) WO2021098715A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116444542A (zh) * 2023-03-31 2023-07-18 广州医科大学 一种噻吩-吩噻嗪化合物及其合成方法和在制备光治疗药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109748884B (zh) * 2019-02-19 2022-06-24 成都恒昊创新科技有限公司 一种铁死亡抑制剂及其制备方法与应用
WO2024062043A1 (en) * 2022-09-21 2024-03-28 Universiteit Antwerpen Substituted phenothiazines as ferroptosis inhibitors
WO2024207131A1 (en) * 2023-04-03 2024-10-10 Sironax (Beijing) Co., Ltd. Ferroptosis inhibitors–phenoxazine acetamides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108484527A (zh) * 2018-04-27 2018-09-04 四川大学 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用
CN109796424A (zh) * 2019-02-19 2019-05-24 四川大学 一种抑制铁死亡的小分子化合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT75871A (en) * 1993-09-30 1997-05-28 Yamanouchi Co Azole derivatives and pharmaceutical compositions thereof
CN109748884B (zh) * 2019-02-19 2022-06-24 成都恒昊创新科技有限公司 一种铁死亡抑制剂及其制备方法与应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108484527A (zh) * 2018-04-27 2018-09-04 四川大学 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用
CN109796424A (zh) * 2019-02-19 2019-05-24 四川大学 一种抑制铁死亡的小分子化合物及其制备方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KI-SUK KIM ETAL.: "The Phenothiazine Drugs Inhibit hERG Potassium Channels" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116444542A (zh) * 2023-03-31 2023-07-18 广州医科大学 一种噻吩-吩噻嗪化合物及其合成方法和在制备光治疗药物中的应用

Also Published As

Publication number Publication date
WO2021098715A1 (zh) 2021-05-27
US20230021442A1 (en) 2023-01-26
CN115052867B (zh) 2024-08-23

Similar Documents

Publication Publication Date Title
CN115052867A (zh) 一种吩噻嗪类铁死亡抑制剂及其制备方法和用途
CN103153994B (zh) 双环杂芳基激酶抑制剂及使用方法
CN111574474B (zh) 一种抑制铁死亡的小分子化合物及其制备方法与应用
WO2014141129A9 (en) Novel methods, compounds, and compositions for inhibition of ros
EP2906564B1 (en) Treating brain cancer using agelastatin a (aa) and analogues thereof
JP2021073257A (ja) 疼痛の治療
Zhao et al. Synthesis and evaluation of new compounds bearing 3-(4-aminopiperidin-1-yl) methyl magnolol scaffold as anticancer agents for the treatment of non-small cell lung cancer via targeting autophagy
CN112739346A (zh) 大麻素及其用途
US9724331B2 (en) Use of maleimide derivatives for preventing and treating leukemia
Cao et al. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment
WO2008109717A1 (en) Compositions and methods for treating cancer
EP3252039B1 (en) Compound containing indoleacetic acid core structure and use thereof
CN110041180A (zh) 含氮杂侧链的紫草素肟衍生物及其制备方法和医药用途
KR20110028626A (ko) Ｈｓｐ９０의 억제제인 피롤로인돌의 신규한 유도체, 그를 함유하는 조성물, 및 그의 용도
López-Rojas et al. Synthesis and biological evaluation of anthracene-9, 10 dione derivatives as CK2 inhibitors
Huang et al. Synthesis and in vitro evaluation of novel spiroketopyrazoles as acetyl-CoA carboxylase inhibitors and potential antitumor agents
CN108884094B (zh) 共晶体
KR20010070381A (ko) 나프토퀴논계 화합물을 포함하는 항암제
EP4286390A1 (en) Heterocyclic amide derivative, preparation method therefor, and application thereof
CN113214097B (zh) 治疗阿尔茨海默病的化合物
CN115583938A (zh) 靶向BCL9/β-连环蛋白互相作用的小分子化合物
JP5955531B2 (ja) 抗癌剤
ES2548789B1 (es) Nuevas cromenoquinonas moduladoras de receptores cannabinoidescb2 con actividad antitumoral
KR102421065B1 (ko) 새로운 퀴논-인돌리진 하이브리드 유도체 제조방법 및 이를 포함하는 항암제 조성물
WO2024120555A2 (en) Prodrugs of benzodiazepine compound and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant